# OnCo record kivu-bioscience (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kivu-bioscience/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kivu-bioscience" ;
  schema:name "Kivu Bioscience"@en ;
  schema:description "Kivu Bioscience develops antibody-drug conjugates that carry fewer drug molecules per antibody, attached at one fixed site, to make them better tolerated. Its first two medicines, against the proteins PTK7 and CEACAM5, entered phase 1 trials in solid tumours in 2026."@en ;
  schema:url <https://onco.cc/companies/kivu-bioscience/>, <https://kivubioscience.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://kivubioscience.com/>, <https://kivubioscience.com/news/kivu-bioscience-raises-92-million-series-a-led-by-novo-holdings-to-advance-next-generation-antibody-drug-conjugates/>, <https://kivubioscience.com/news/kivu-bioscience-announces-first-patient-dosed-in-phase-1-trial-of-kivu-107-next-generation-ptk7-targeting-adc-for-advanced-solid-tumors/>, <https://kivubioscience.com/news/kivu-bioscience-presents-kivu-305-preclinical-data-at-world-adc-london-2026-and-advances-into-phase-1-clinical-trial/> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ptk7/>, <https://onco.cc/targets/ceacam5/> .